These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 37397990)

  • 61. Paclitaxel Resistance Modulated by the Interaction between TRPS1 and AF178030.2 in Triple-Negative Breast Cancer.
    Zhao T; Zhang T; Zhang Y; Zhou B; Lu X
    Evid Based Complement Alternat Med; 2022; 2022():6019975. PubMed ID: 35399640
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Combined kinase inhibitors of MEK1/2 and either PI3K or PDGFR are efficacious in intracranial triple-negative breast cancer.
    Van Swearingen AED; Sambade MJ; Siegel MB; Sud S; McNeill RS; Bevill SM; Chen X; Bash RE; Mounsey L; Golitz BT; Santos C; Deal A; Parker JS; Rashid N; Miller CR; Johnson GL; Anders CK
    Neuro Oncol; 2017 Oct; 19(11):1481-1493. PubMed ID: 28486691
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Persistent EGFR/K-RAS/SIAH pathway activation drives chemo-resistance and early tumor relapse in triple-negative breast cancer.
    Tang AH; Hoefer RA; Guye ML; Bear HD
    Cancer Drug Resist; 2022; 5(3):691-702. PubMed ID: 36176751
    [TBL] [Abstract][Full Text] [Related]  

  • 64. PSMB5 is associated with proliferation and drug resistance in triple-negative breast cancer.
    Wei W; Zou Y; Jiang Q; Zhou Z; Ding H; Yan L; Yang S
    Int J Biol Markers; 2018 Jan; 33(1):102-108. PubMed ID: 28623645
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Serotonin 5-HT7 receptor is a biomarker poor prognostic factor and induces proliferation of triple-negative breast cancer cells through FOXM1.
    Cınar V; Hamurcu Z; Guler A; Nurdinov N; Ozpolat B
    Breast Cancer; 2022 Nov; 29(6):1106-1120. PubMed ID: 36006564
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Antagonistic Pharmacological Interaction between Sirtuin Inhibitor Cambinol and Paclitaxel in Triple-Negative Breast Cancer Cell Lines: An Isobolographic Analysis.
    Wawruszak A; Luszczki J; Okon E; Czerwonka A; Stepulak A
    Int J Mol Sci; 2022 Jun; 23(12):. PubMed ID: 35742901
    [TBL] [Abstract][Full Text] [Related]  

  • 67. A novel orally available seleno-purine molecule suppresses triple-negative breast cancer cell proliferation and progression to metastasis by inducing cytostatic autophagy.
    Chang CH; Bijian K; Wernic D; Su J; da Silva SD; Yu H; Qiu D; Asslan M; Alaoui-Jamali MA
    Autophagy; 2019 Aug; 15(8):1376-1390. PubMed ID: 30773992
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Eribulin Synergistically Increases Anti-Tumor Activity of an mTOR Inhibitor by Inhibiting pAKT/pS6K/pS6 in Triple Negative Breast Cancer.
    Wen W; Marcinkowski E; Luyimbazi D; Luu T; Xing Q; Yan J; Wang Y; Wu J; Guo Y; Tully D; Han ES; Yost SE; Yuan Y; Yim JH
    Cells; 2019 Aug; 8(9):. PubMed ID: 31480338
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Nab-paclitaxel for the treatment of triple-negative breast cancer: Rationale, clinical data and future perspectives.
    Schettini F; Giuliano M; De Placido S; Arpino G
    Cancer Treat Rev; 2016 Nov; 50():129-141. PubMed ID: 27665540
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Silibinin induces metabolic crisis in triple-negative breast cancer cells by modulating EGFR-MYC-TXNIP axis: potential therapeutic implications.
    Iqbal MA; Chattopadhyay S; Siddiqui FA; Ur Rehman A; Siddiqui S; Prakasam G; Khan A; Sultana S; Bamezai RN
    FEBS J; 2021 Jan; 288(2):471-485. PubMed ID: 32356386
    [TBL] [Abstract][Full Text] [Related]  

  • 71. KIF11 is required for proliferation and self-renewal of docetaxel resistant triple negative breast cancer cells.
    Jiang M; Zhuang H; Xia R; Gan L; Wu Y; Ma J; Sun Y; Zhuang Z
    Oncotarget; 2017 Nov; 8(54):92106-92118. PubMed ID: 29190901
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Regulator of G protein signaling 20 correlates with clinicopathological features and prognosis in triple-negative breast cancer.
    Li Q; Jin W; Cai Y; Yang F; Chen E; Ye D; Wang Q; Guan X
    Biochem Biophys Res Commun; 2017 Apr; 485(3):693-697. PubMed ID: 28237701
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Knockdown of lncRNA H19 restores chemo-sensitivity in paclitaxel-resistant triple-negative breast cancer through triggering apoptosis and regulating Akt signaling pathway.
    Han J; Han B; Wu X; Hao J; Dong X; Shen Q; Pang H
    Toxicol Appl Pharmacol; 2018 Nov; 359():55-61. PubMed ID: 30244121
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Cdh1 Deficiency Sensitizes TNBC Cells to PARP Inhibitors.
    Li J; Lan M; Peng J; Xiong Q; Xu Y; Yang Y; Zhou Y; Liu J; Zeng Z; Yang X; Zhang Z; Zhang P; Zhu Q; Wu W
    Genes (Basel); 2022 Apr; 13(5):. PubMed ID: 35627188
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Phosphatase PTP4A3 Promotes Triple-Negative Breast Cancer Growth and Predicts Poor Patient Survival.
    den Hollander P; Rawls K; Tsimelzon A; Shepherd J; Mazumdar A; Hill J; Fuqua SA; Chang JC; Osborne CK; Hilsenbeck SG; Mills GB; Brown PH
    Cancer Res; 2016 Apr; 76(7):1942-53. PubMed ID: 26921331
    [TBL] [Abstract][Full Text] [Related]  

  • 76. MCAK and paclitaxel have differential effects on spindle microtubule organization and dynamics.
    Rizk RS; Bohannon KP; Wetzel LA; Powers J; Shaw SL; Walczak CE
    Mol Biol Cell; 2009 Mar; 20(6):1639-51. PubMed ID: 19158381
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Inhibition of RPTOR overcomes resistance to EGFR inhibition in triple-negative breast cancer cells.
    You KS; Yi YW; Kwak SJ; Seong YS
    Int J Oncol; 2018 Mar; 52(3):828-840. PubMed ID: 29344641
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Prognostic Value of a Glycolytic Signature and Its Regulation by Y-Box-Binding Protein 1 in Triple-Negative Breast Cancer.
    Lai YW; Hsu WJ; Lee WY; Chen CH; Tsai YH; Dai JZ; Yang CC; Lin CW
    Cells; 2021 Jul; 10(8):. PubMed ID: 34440660
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Synthesis of micellar-like terpolymer nanoparticles with reductively-cleavable cross-links and evaluation of efficacy in 2D and 3D models of triple negative breast cancer.
    Monteiro PF; Gulfam M; Monteiro CJ; Travanut A; Abelha TF; Pearce AK; Jerôme C; Grabowska AM; Clarke PA; Collins HM; Heery DM; Gershkovich P; Alexander C
    J Control Release; 2020 Jul; 323():549-564. PubMed ID: 32371266
    [TBL] [Abstract][Full Text] [Related]  

  • 80. BCL6 and the Notch pathway: a signaling axis leading to a novel druggable biotarget in triple negative breast cancer.
    De Santis F; Romero-Cordoba SL; Castagnoli L; Volpari T; Faraci S; Fucà G; Tagliabue E; De Braud F; Pupa SM; Di Nicola M
    Cell Oncol (Dordr); 2022 Apr; 45(2):257-274. PubMed ID: 35357654
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.